Biomarkers for Alzheimer's disease drug development:
This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer's disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehens...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York, NY
Springer New York
2018
|
| Ausgabe: | 1st ed. 2018 |
| Schriftenreihe: | Methods in Molecular Biology
1750 |
| Schlagworte: | |
| Online-Zugang: | UBR01 TUM01 Volltext |
| Zusammenfassung: | This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer's disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer's disease, cutting-edge developments in neuropathology and their relevance for Alzheimer's disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field. |
| Beschreibung: | Epidemiology of Dementia: The Burden on Society, the Challenges for Research -- Population-based Approaches to Alzheimer's Disease Prevention -- Systems Biology Methods for Alzheimer's Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials -- CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform -- CSF N-glycomics using MALDI MS Techniques in Alzheimer's Disease -- MicroRNA Profiling of Alzheimer's Disease Cerebrospinal Fluid -- Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma -- Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer's Disease Research -- Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases -- Functional Magnetic Resonance Imaging in Alzheimer' Disease Drug Development -- - Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies -- Hybrid PET-MRI in Alzheimer's Disease Research -- Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers -- The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer's Dementia -- Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography -- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach -- Unbiased Lipidomics and Metabolomics of Human Brain Samples -- Neuropathological Assessment as an Endpoint in Clinical Trial Design -- Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer's Disease Biomarker Discovery -- Telomere length shortening in Alzheimer's disease - procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study -- Quantifying miRNA Deregulation in Alzheimer's Disease -- - Imaging of Microglial Activation in Alzheimer's Disease by [11C]PBR28 PET -- In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models -- Cognitive Assessment in Alzheimer's Disease Clinical Trials -- Data Mining and Machine Learning Methods for Dementia Research. |
| Beschreibung: | 1 Online-Ressource (XV, 372 Seiten) Illustrationen |
| ISBN: | 9781493977048 |
| DOI: | 10.1007/978-1-4939-7704-8 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047626859 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 211206s2018 |||| o||u| ||||||eng d | ||
| 020 | |a 9781493977048 |c Online |9 978-1-4939-7704-8 | ||
| 024 | 7 | |a 10.1007/978-1-4939-7704-8 |2 doi | |
| 035 | |a (ZDB-2-PRO)978-1-4939-7704-8 | ||
| 035 | |a (OCoLC)1289767516 | ||
| 035 | |a (DE-599)BVBBV047626859 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-91 | ||
| 082 | 0 | |a 615 | |
| 245 | 1 | 0 | |a Biomarkers for Alzheimer's disease drug development |c edited by Robert Perneczky |
| 250 | |a 1st ed. 2018 | ||
| 264 | 1 | |a New York, NY |b Springer New York |c 2018 | |
| 300 | |a 1 Online-Ressource (XV, 372 Seiten) |b Illustrationen | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Methods in Molecular Biology | |
| 490 | 0 | |a 1750 | |
| 500 | |a Epidemiology of Dementia: The Burden on Society, the Challenges for Research -- Population-based Approaches to Alzheimer's Disease Prevention -- Systems Biology Methods for Alzheimer's Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials -- CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform -- CSF N-glycomics using MALDI MS Techniques in Alzheimer's Disease -- MicroRNA Profiling of Alzheimer's Disease Cerebrospinal Fluid -- Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma -- Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer's Disease Research -- Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases -- Functional Magnetic Resonance Imaging in Alzheimer' Disease Drug Development -- | ||
| 500 | |a - Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies -- Hybrid PET-MRI in Alzheimer's Disease Research -- Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers -- The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer's Dementia -- Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography -- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach -- Unbiased Lipidomics and Metabolomics of Human Brain Samples -- Neuropathological Assessment as an Endpoint in Clinical Trial Design -- Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer's Disease Biomarker Discovery -- Telomere length shortening in Alzheimer's disease - procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study -- Quantifying miRNA Deregulation in Alzheimer's Disease -- | ||
| 500 | |a - Imaging of Microglial Activation in Alzheimer's Disease by [11C]PBR28 PET -- In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models -- Cognitive Assessment in Alzheimer's Disease Clinical Trials -- Data Mining and Machine Learning Methods for Dementia Research. | ||
| 520 | |a This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer's disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer's disease, cutting-edge developments in neuropathology and their relevance for Alzheimer's disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field. | ||
| 650 | 4 | |a Pharmacology | |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 700 | 1 | |a Perneczky, Robert |d 1975- |0 (DE-588)129318663 |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493977031 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493977055 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781493992621 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4939-7704-8 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-PRO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033011347 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-4939-7704-8 |l UBR01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1007/978-1-4939-7704-8 |l TUM01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804183069535502336 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author2 | Perneczky, Robert 1975- |
| author2_role | edt |
| author2_variant | r p rp |
| author_GND | (DE-588)129318663 |
| author_facet | Perneczky, Robert 1975- |
| building | Verbundindex |
| bvnumber | BV047626859 |
| collection | ZDB-2-PRO |
| ctrlnum | (ZDB-2-PRO)978-1-4939-7704-8 (OCoLC)1289767516 (DE-599)BVBBV047626859 |
| dewey-full | 615 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615 |
| dewey-search | 615 |
| dewey-sort | 3615 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| doi_str_mv | 10.1007/978-1-4939-7704-8 |
| edition | 1st ed. 2018 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05050nmm a2200481zc 4500</leader><controlfield tag="001">BV047626859</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">211206s2018 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781493977048</subfield><subfield code="c">Online</subfield><subfield code="9">978-1-4939-7704-8</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4939-7704-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-PRO)978-1-4939-7704-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1289767516</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047626859</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biomarkers for Alzheimer's disease drug development</subfield><subfield code="c">edited by Robert Perneczky</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2018</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer New York</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XV, 372 Seiten)</subfield><subfield code="b">Illustrationen</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Methods in Molecular Biology</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">1750</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Epidemiology of Dementia: The Burden on Society, the Challenges for Research -- Population-based Approaches to Alzheimer's Disease Prevention -- Systems Biology Methods for Alzheimer's Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials -- CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform -- CSF N-glycomics using MALDI MS Techniques in Alzheimer's Disease -- MicroRNA Profiling of Alzheimer's Disease Cerebrospinal Fluid -- Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma -- Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer's Disease Research -- Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases -- Functional Magnetic Resonance Imaging in Alzheimer' Disease Drug Development -- </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a"> - Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies -- Hybrid PET-MRI in Alzheimer's Disease Research -- Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers -- The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer's Dementia -- Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography -- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach -- Unbiased Lipidomics and Metabolomics of Human Brain Samples -- Neuropathological Assessment as an Endpoint in Clinical Trial Design -- Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer's Disease Biomarker Discovery -- Telomere length shortening in Alzheimer's disease - procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study -- Quantifying miRNA Deregulation in Alzheimer's Disease -- </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a"> - Imaging of Microglial Activation in Alzheimer's Disease by [11C]PBR28 PET -- In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models -- Cognitive Assessment in Alzheimer's Disease Clinical Trials -- Data Mining and Machine Learning Methods for Dementia Research. </subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer's disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer's disease, cutting-edge developments in neuropathology and their relevance for Alzheimer's disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field. </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Perneczky, Robert</subfield><subfield code="d">1975-</subfield><subfield code="0">(DE-588)129318663</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493977031</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493977055</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781493992621</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4939-7704-8</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-PRO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033011347</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4939-7704-8</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4939-7704-8</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV047626859 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T18:44:32Z |
| indexdate | 2024-07-10T09:17:35Z |
| institution | BVB |
| isbn | 9781493977048 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033011347 |
| oclc_num | 1289767516 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| owner_facet | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (XV, 372 Seiten) Illustrationen |
| psigel | ZDB-2-PRO |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | Springer New York |
| record_format | marc |
| series2 | Methods in Molecular Biology 1750 |
| spelling | Biomarkers for Alzheimer's disease drug development edited by Robert Perneczky 1st ed. 2018 New York, NY Springer New York 2018 1 Online-Ressource (XV, 372 Seiten) Illustrationen txt rdacontent c rdamedia cr rdacarrier Methods in Molecular Biology 1750 Epidemiology of Dementia: The Burden on Society, the Challenges for Research -- Population-based Approaches to Alzheimer's Disease Prevention -- Systems Biology Methods for Alzheimer's Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials -- CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform -- CSF N-glycomics using MALDI MS Techniques in Alzheimer's Disease -- MicroRNA Profiling of Alzheimer's Disease Cerebrospinal Fluid -- Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma -- Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer's Disease Research -- Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases -- Functional Magnetic Resonance Imaging in Alzheimer' Disease Drug Development -- - Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies -- Hybrid PET-MRI in Alzheimer's Disease Research -- Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers -- The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer's Dementia -- Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography -- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach -- Unbiased Lipidomics and Metabolomics of Human Brain Samples -- Neuropathological Assessment as an Endpoint in Clinical Trial Design -- Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer's Disease Biomarker Discovery -- Telomere length shortening in Alzheimer's disease - procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study -- Quantifying miRNA Deregulation in Alzheimer's Disease -- - Imaging of Microglial Activation in Alzheimer's Disease by [11C]PBR28 PET -- In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models -- Cognitive Assessment in Alzheimer's Disease Clinical Trials -- Data Mining and Machine Learning Methods for Dementia Research. This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer's disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer's disease, cutting-edge developments in neuropathology and their relevance for Alzheimer's disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field. Pharmacology (DE-588)4143413-4 Aufsatzsammlung gnd-content Perneczky, Robert 1975- (DE-588)129318663 edt Erscheint auch als Druck-Ausgabe 9781493977031 Erscheint auch als Druck-Ausgabe 9781493977055 Erscheint auch als Druck-Ausgabe 9781493992621 https://doi.org/10.1007/978-1-4939-7704-8 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Biomarkers for Alzheimer's disease drug development Pharmacology |
| subject_GND | (DE-588)4143413-4 |
| title | Biomarkers for Alzheimer's disease drug development |
| title_auth | Biomarkers for Alzheimer's disease drug development |
| title_exact_search | Biomarkers for Alzheimer's disease drug development |
| title_exact_search_txtP | Biomarkers for Alzheimer's disease drug development |
| title_full | Biomarkers for Alzheimer's disease drug development edited by Robert Perneczky |
| title_fullStr | Biomarkers for Alzheimer's disease drug development edited by Robert Perneczky |
| title_full_unstemmed | Biomarkers for Alzheimer's disease drug development edited by Robert Perneczky |
| title_short | Biomarkers for Alzheimer's disease drug development |
| title_sort | biomarkers for alzheimer s disease drug development |
| topic | Pharmacology |
| topic_facet | Pharmacology Aufsatzsammlung |
| url | https://doi.org/10.1007/978-1-4939-7704-8 |
| work_keys_str_mv | AT perneczkyrobert biomarkersforalzheimersdiseasedrugdevelopment |